Free bisexual chat line trial
"This is an important step forward in the treatment of a terrible disease, and hopefully this platform for synergistic drug delivery will continue to advance the field." VYXEOS also demonstrated a statistically significant improvement in induction response rate (CR CRi of 47.7% versus 33.3%; p=0.016) and this significance was maintained for the analysis of CR alone (CR of 37.3% versus 25.6%, p=0.040).
Thirty-four percent of VYXEOS treated patients received a stem cell transplant (SCT) compared to 25% of 7 3 treated patients.
Celator has also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation.AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. Furthermore, approximately half of those patients are considered suitable for intensive treatment.The American Cancer Society estimates that there will be 19,950 new cases of AML and 10,430 deaths from AML in the U. Even with current treatment, overall survival for AML is poor.In patients over 60 years of age, the 5 year survival rate is less than 10%.In high-risk (secondary) AML, overall survival is lower, resulting in an acute need for new treatment options for these patients. Celator Pharmaceuticals, Inc., with locations in , is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer.
Event-free survival was also statistically significant in favor of VYXEOS. The median event-free survival was 2.53 months in the VYXEOS arm compared to 1.31 months in the 7 3 arm.